Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medx Health Corp V.MDX

Alternate Symbol(s):  MDXHF

MedX Health Corp. is a medical device and software company. It develops and manufactures skin-related screening tools and phototherapy devices for pain relief and tissue repair. It focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is a medical device technology that is used to scan skin for suspicious moles and lesions and, including DermSecure, its telemedicine software application, and phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode to provide treatment of pain and tissue damage in the rehabilitation market. Its products SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimeters beneath suspicious moles and lesions in a pain free, non-invasive manner. Its SIAscopy on DermSecure telemedicine platform enables the Web-based operation of its SIAscopy scanning technology.


TSXV:MDX - Post by User

Post by Insightful1on Dec 01, 2021 1:28am
482 Views
Post# 34183564

MedX continues to deliver on strategic initiatives

MedX continues to deliver on strategic initiativesMedX announced they would be commencing the global roll-out of their DernSecure platform, this rolll-out would take the form of paid pilots once the distribution /channel partners were selected. The pilots were to determine the best approach to successful patient outcomes over a period of 3-6 months after which a commercial distribution aggrement would be struck. MedX advised investors they would be able to gage the commercial success by the number of pilots that turned into commercial agreements. All commercial agreements would have minimum performance numbesr built into the agreements. This latest announcement shows continued progress on selecting exceptional potential partners.
 
Seth Rankin stated; “At London Medical Laboratory, we were seeking a world-class, innovative teledermatology partner for our patients and we found such a partner in MedX – their image capture system is the best available on the market today,” said Seth Rankin, CEO, London Medical Laboratory Ltd. “We look forward to working with MedX to make this leading technology available to the UK patients who need it most.”

Who is Seth Rankin? 


https://healthpad.net/provider/profile/3913/seth-rankin/

Who is London Doctor Clinics? 

https://www.londondoctorsclinic.co.uk/

This represents 5 major distribution agreements since September 27th. It appears under the leadership of Sylvain Desjeans MedX is now able to execute as they stated. 


<< Previous
Bullboard Posts
Next >>